Gene and cell therapy workflows frequently utilize HEK293/293T cells in the production of viral vectors.
Both regulators and manufacturers alike are looking to standardize best practices around viral vector production workflows. Avoiding the use of animal-derived reagents and using assurance of clonality as part of production quality control was highlighted in regards to patient safety.
In this paper we evaluated two technologies, both already well accepted in CHO-based cell line development workflows, for their suitability with HEK cells. Read how the use of VIPS and InstiGRO HEK were found to be a strong combination for developing HEK based cell lines whilst delivering on the regulatory demands for clonally-derived Master Cell Banks.